News

BIVN-401 was given to 25 patients with genotype 4 hepatitis C who had failed a prior treatment. The drug was given orally for 100 days and measurement of

Medicago will receive milestone payments from Acambis to assess the feasibility of using Medicago’s Proficia protein technology for the production of vaccines. “We believe that our Proficia technology

Researchers used neurotensin receptor knock-out mice to conclusively identify the neurotensin NTR1 receptor as the specific site through which CGX-1160 produces analgesia. A series of in vitro experiments

The patent covers RNA interference (RNAi) mediated inhibition of gene expression using short-interfering ribonucleic acids (siRNA), broadly covering any siRNA molecule which targets conserved sequences within a virus

“This phase IIa study in hepatitis C patients with celgosivir as monotherapy, along with the safety and nonclinical synergy data generated to date, supports our combination therapy development

The EMEA orphan drug designation provides incentives to companies that develop drugs for diseases affecting no more than 50 in 100,000 persons in the European Union, or drugs

Similar to development stage in-licensing deals, the terms of the agreement provide for success-based milestones per compound and royalties on the commercialization of drugs repositioned through Gene Logic’s

A new drug application for Preos is currently under review by the FDA. The European Medicines Agency is also reviewing the market authorization application for Preotact, the European

In this double-blind phase II study, 33 patients received either 400mg or 1200mg of 2-methoxyestradiol per day. Seven patients treated at the higher dose level, and one patient